Rectal absorption of flecainide acetate. 1988

L Lie-A-Huen, and J H Kingma
Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.

The rectal absorption of flecainide from an aqueous solution, a fatty suppository and a polyethyleneglycol suppository was studied in one patient with supraventricular tachycardia (Wolff-Parkinson-White syndrome) refractory for oral anti-arrhythmic treatment. Rectal absorption was found to be fast (t1/2abs = 1 h) and complete when flecainide was administered as a solution (relative bioavailability 100%). Flecainide was poorly absorbed from a fatty suppository. The polyethyleneglycol suppository gave absorption with a relative bioavailability of 80% and t1/2 abs = 1.2 h.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008297 Male Males
D012007 Rectum The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL. Rectums
D005424 Flecainide A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS. Flecainide Acetate,Apocard,Flecadura,Flecainid-Isis,Flecainide Monoacetate,Flecainide Monoacetate, (+-)-Isomer,Flecainide Monoacetate, (R)-Isomer,Flecainide Monoacetate, (S)-Isomer,Flecainide, (R)-Isomer,Flecainide, (S)-Isomer,Flecainide, 5-HO-N-(6-oxo)-Derivative,Flecainide, 5-HO-N-(6-oxo)-Derivative, (+-)-Isomer,Flecatab,Flécaïne,R818,Tambocor,Flecainid Isis
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013050 Spectrometry, Fluorescence Measurement of the intensity and quality of fluorescence. Fluorescence Spectrophotometry,Fluorescence Spectroscopy,Spectrofluorometry,Fluorescence Spectrometry,Spectrophotometry, Fluorescence,Spectroscopy, Fluorescence
D013270 Stomach An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the ESOPHAGUS and the beginning of the DUODENUM. Stomachs

Related Publications

L Lie-A-Huen, and J H Kingma
May 1996, Annales de cardiologie et d'angeiologie,
L Lie-A-Huen, and J H Kingma
January 1987, Critical care nurse,
L Lie-A-Huen, and J H Kingma
January 1984, Lancet (London, England),
L Lie-A-Huen, and J H Kingma
August 1979, Clinical pharmacology and therapeutics,
L Lie-A-Huen, and J H Kingma
February 1984, The American journal of cardiology,
L Lie-A-Huen, and J H Kingma
February 1984, The American journal of cardiology,
L Lie-A-Huen, and J H Kingma
February 2011, Journal of pharmaceutical sciences,
L Lie-A-Huen, and J H Kingma
June 1985, The New Zealand medical journal,
L Lie-A-Huen, and J H Kingma
December 1990, DICP : the annals of pharmacotherapy,
L Lie-A-Huen, and J H Kingma
March 1988, Cardiovascular drugs and therapy,
Copied contents to your clipboard!